The comparison of seroconversion rates among different varicella vaccines administered Turkish children; MAV/06 and vOka

Basit Öğe Kaydı
dc.authoridBağ, Özlem/0000-0003-2178-4695
dc.authoridGüner Özenen, Gizem/0000-0002-9725-7501
dc.authoridUmit, Zuhal/0000-0003-4246-5458
dc.authoridSahbudak Bal, Zumrut/0000-0001-9189-8220
dc.authorscopusid57209535255
dc.authorscopusid38061964200
dc.authorscopusid6602884995
dc.authorscopusid57298693400
dc.authorscopusid6507824544
dc.authorscopusid57221502271
dc.authorscopusid7004343654
dc.authorwosidBağ, Özlem/H-8574-2018
dc.authorwosidGüner Özenen, Gizem/ABG-2316-2021
dc.contributor.authorUmit, Zuhal
dc.contributor.authorBal, Zumrut Sahbudak
dc.contributor.authorZeytinoglu, Aysin
dc.contributor.authorAydogan, Tansu Gulbahar
dc.contributor.authorBag, Ozlem
dc.contributor.authorOzenen, Gizem Guner
dc.contributor.authorOzkinay, Ferda
dc.date.accessioned2023-01-12T20:00:06Z
dc.date.available2023-01-12T20:00:06Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractVaricella is a vaccine-preventable disease, and the incidence of varicella has declined since the introduction of varicella vaccine campaigns. A wild type of varicella zoster virus (VZV) was isolated from a 33-month-old child with varicella in Korea in 1989, a different strain (MAV/06). A live-attenuated varicella vaccine containing strain (MAV/06), Suduvax (R), was developed in South Korea in 1994. Turkey introduced the varicella vaccine containing the MAV/06 strain (Varicella Vaccine-GCC, Green Cross, South Korea) in January 2019. Therefore, we aimed to compare the seroconversion rates among MAV/06 vaccine- and vOka-administered children. We prospectively collected blood samples from 98 received vOKA and 98 received MAV/06 children 6 weeks after administration, and seroconversion rates were determined by an indirect fluorescence assay (Anti-VZV IIFT IgG, Euroimmun, Germany). Seroconversion rate was significantly higher in vOka group than MAV/06 group (82.7% vs. 64.3%; p = .004). Of the children vaccinated with vOka strain, 17 children did not develop antibodies, 12 were weakly positive, and the remaining 69 children were strongly positive. Of the children who were administered MAV/06 strain, 35 were negative, 20 were weakly positive, and 43 were strongly positive. In conclusion, this study demonstrated that MAV/06 varicella vaccine had lower seroconversion rates and the strong seropositive cases were less common than vOka-administered children. Larger and prospective studies are needed.en_US
dc.identifier.doi10.1080/21645515.2021.1967037
dc.identifier.endpage4193en_US
dc.identifier.issn2164-5515
dc.identifier.issn2164-554X
dc.identifier.issue11en_US
dc.identifier.pmid34643479en_US
dc.identifier.scopus2-s2.0-85117216280en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage4190en_US
dc.identifier.urihttps://doi.org/10.1080/21645515.2021.1967037
dc.identifier.urihttps://hdl.handle.net/11454/77288
dc.identifier.volume17en_US
dc.identifier.wosWOS:000707091800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofHuman Vaccines & Immunotherapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVaricellaen_US
dc.subjectvaricella vaccineen_US
dc.subjectSuduvaxen_US
dc.subjectMAVen_US
dc.subject06en_US
dc.subjectvOkaen_US
dc.subjectseroconversionen_US
dc.subjectZoster-Virusen_US
dc.subjectVaccinationen_US
dc.titleThe comparison of seroconversion rates among different varicella vaccines administered Turkish children; MAV/06 and vOkaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu